AstraZeneca's lengthy and turbulent development of CTLA4 inhibitor tremelimumab has at least led to a regulatory approval as part of a combination therapy for advanced liver cancer. Tremelimumab ...

Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a ...

Animal experiments indicate that CTLA4-Ig has the potential to block unwanted immune responses without compromising the ability to fight off other infections. BMS is testing CTLA4 in humans for ...

In September 30 Nature Immunology, Ursula Grohmann and colleagues at the University of Perugia, Italy, show that CTLA-4–Ig modulates tryptophan catabolism and acts as a ligand for B7 receptor ...

The study is assessing the safety and biological effects of a combination therapy involving LD IL-2 and CTLA4-Ig. The data from this ongoing study will contribute to the design features of the ...

and/or 0.2 mg/dose CTLA-4-Ig (days 0, 2, 4 and 6 after transplantation). Control recipients received 0.25 mg/dose hamster IgG (days 0, 2, 4, 7 and 10). The grafts were observed daily. Rejection ...